HYPID (Pulmonary Hypertension in Interstitial Lung Disease) EXTENSION

Launched by GROUPE D'ETUDES ET DE RECHERCHE SUR LES MALADIES ORPHELINES PULMONAIRES · Jun 9, 2016

Keywords

ClinConnect Summary

Pre capillary pulmonary hypertension (PH) may be present in patients with diffuse interstitial lung disease.

In this context, PH represents an important factor of morbidity and mortality for these patients.

As in HYPID, the main purpose of HYPID-2 is to determine predictive factors of mortality within this cohort of incident patients (i.e patients included within 6 months after PH diagnosis).

In order to reach that aim,the study includes an evaluation based on exams conducted for the routine follow-up of incident patients.

Each incident patient will be followed during 2 years at least.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• Patients newly diagnosed with:
• • Pre capillary pulmonary hypertension at right heart sided catheterization with: mPAP \> or = 25 mmHg, PCWP \< or = 15 mmHg
• • Interstitial lung disease with diffuse infiltrative opacities on chest CT scan
• Exclusion Criteria:
• • Pulmonary hypertension related to a thromboembolic disease
• • Respiratory disease other than diffuse interstitial lung disease
• • Any etiological factor of pulmonary arterial hypertension based on NICE 2013 classification other than diffuse interstitial lung disease
• • Any progressive disease associated to a life expectancy less than 6 months other than pulmonary hypertension, diffuse interstitial lung disease and respiratory insufficiency